#United States #San Diego #Class Action #Robbins LLP #Replimune

Robbins LLP Encourages REPL Investors to Act

In an urgent appeal for Replimune investors, Robbins LLP, a law firm specializing in shareholder rights, has announced the filing of a class-action lawsuit aimed at protecting those who acquired Replimune Group, Inc. (NASDAQ: REPL) securities from October 20, 2025, to April 10, 2026. This legal action addresses significant losses that many investors faced following the substantial decline in the company's stock value.

Understanding the Basis of the Lawsuit

The lawsuit stems from allegations that Replimune misrepresented key details regarding its lead cancer therapy product, RP1 (vusolimogene oderparepvec). The company positioned itself as an innovator in clinical-stage biotechnology, focused on developing unique oncolytic immunotherapies. However, the complaint asserts that investors were misled about the efficacy of RP1.

On October 20, 2025, Replimune announced that the U.S. Food and Drug Administration (FDA) had accepted the resubmission of its Biologics License Application (BLA) for RP1. Investors were assured that this submission included additional supporting data intended to satisfy previous concerns expressed by the FDA. However, the lawsuit alleges that critical issues regarding study design raised by the FDA were not adequately addressed—specifically, the lack of a complete clinical study supporting RP1's approval.

The Downward Spiral of REPL Stock

The turning point for investors came on April 10, 2026. During trading hours, the FDA issued a Complete Response Letter (CRL), publicly rejecting Replimune’s BLA for RP1. The letter cited several deficiencies related to the company's clinical trials, deeming them insufficient for regulatory approval. As a result, Replimune’s stock plummeted dramatically, closing down over 19% on the same day.

By April 13, the company further acknowledged in a press release that the FDA had preferred a randomized controlled trial, yet claimed an exploratory data analysis might be acceptable. Following this news, the stock price dropped even further, resulting in a cumulative loss for many investors.

Who Can Join the Class Action?

Robbins LLP aims to assist those who purchased Replimune securities during the defined Class Period and experienced financial losses. There is a definitive timeline to act—investors potentially eligible for participation must contact Robbins LLP before the lead plaintiff application deadline of October 5, 2026. This opportunity allows investors to not only regain their lost investments but also to hold the company accountable for its alleged misleading practices.

No Cost to Participate

It’s important to note that Robbins LLP operates on a contingency fee basis. This means that involved investors do not bear any upfront costs for legal representation; fees will only apply if a successful recovery is achieved. This aspect significantly reduces the financial risk for investors wishing to pursue claims against Replimune and its affiliates.

Conclusion

The Replimune case emphasizes the critical need for transparency in biotech investments, particularly in a field where the stakes are high and investor confidence is paramount. Shareholders affected by Replimune's stock decline have a crucial opportunity to join this class action, advocate for their rights, and potentially recover losses. For further information, interested parties are encouraged to reach out to Robbins LLP or visit their website to learn about their rights under federal securities laws.

For more details or inquiries, investors may contact attorney Aaron Dumas, Jr., or call Robbins LLP directly at (800) 350-6003.